• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Amorphous Solid Dispersions for Bioavailability Enhancement

    Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success

    Manufacturing Dietary Supplements in Economic Uncertainty

    2023 Contract Manufacturing Survey

    New Possibilities for Small Batch Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories

    Vantage Nutrition Acquires ComboCap

    Secarna, SciNeuro Enter Research Agreement for CNS Diseases

    BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines

    Codiak BioSciences to File for Chapter 11
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    PharmaBlock Opens New R&D Facility in Pennsylvania

    Macfarlan Smith Annan Facility Marked for Closure  

    Northwest Bio, Advent BioServices Gain MHRA License for Commercial Manufacturing

    Willow, Suanfarma Complete Manufacturing Process for Cannabigerol

    Harm Reduction Therapeutics, Catalent Ink Naloxone Commercial Supply Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Adare Pharma Solutions Chooses Vantage to Lead Packaging Facility Upgrade

    This is Sofgen Pharmaceuticals

    Why Sofgen Pharmaceuticals?

    Stevanato, Recipharm Partner to Develop Pre-fillable Syringes for Soft Mist Inhaler

    Chewgels™ - An Explosive Experience with Innovative Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories

    Secarna, SciNeuro Enter Research Agreement for CNS Diseases

    Pharming Gets FDA Nod for Joenja

    PharmaBlock Opens New R&D Facility in Pennsylvania

    Catalent Licenses Formulation Technology to Deliver High-Concentration Biologics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Grand River Aseptic Manufacturing Receives Zero Observations from FDA Inspection

    Sofgen's Center for Pharmaceutical Excellence (CPhE)

    Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success

    What Does the Future of Gene Therapy Hold?

    Automated Regulatory Electronic Publishing: How is It Changing the Industry?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    INCOG BioPharma Services

    Lannett CDMO

    LOTTE BIOLOGICS

    TaiMed Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    INCOG BioPharma Services

    Lannett CDMO

    LOTTE BIOLOGICS

    TaiMed Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Using Pragmatic Randomization in Real-World Studies

    How PCTs increase the robustness of real world studies at a fraction of the cost of classic randomized trials

    Nancy Dreyer, MPH, Ph.D. , Global Chief of Scientific Affairs and Senior Vice President, Real-World & Late Phase Research, QuintilesIMS05.22.17
    Real world observational studies are gaining prominence as a way to gather valuable information about the impact of a treatment outside of the highly controlled clinical trial environment. Observational studies track the behavior and real world outcomes of diverse patients at various stages of disease, helping researchers learn which treatments result in clinically meaningful improvement, for which type of patients and in what situations. Observational studies can also provide information about treatment heterogeneity that is needed to develop a more personalized approach to medical care. By definition, observational studies do not interfere with decisions about which treatments patients will be offered. Instead of dictating which treatments will be used, “observational” studies rely instead on information that is captured through the normal course of treatment, whatever that may be, and require limited, if any, additional testing.

    The challenge with these studies is the unintended bias that determines how patients are treated.

    When a new treatment comes to market, it is often first prescribed to patients who have failed to respond to other treatments, and who may start on a new drug as a last resort, when their disease progressed beyond reversal or they have tried every other treatment without any benefit. As a result, they may have outcomes that are quite different than would be encountered without the bias that can result from “channeling” sicker patients to new treatments.

    To overcome this bias, some researchers use pragmatic randomized clinical trials (PCT), where treatment randomization is used to balance baseline characteristics and risk factors between treatment groups. Then information collected from observing encounters in everyday medical practice is used to gauge practical impacts on patients’ diseases. PCTs are gaining popularity as a way to quickly and less expensively evaluate the real world impact of marketed products, at lower cost and with less complexity than randomized clinical trials (RCTs).

    Once physicians and patients agree to participate in a PCT, the investigator follows a randomization schedule to assign treatment and then conducts follow-up according to customary clinical practice. Treatments are not blinded. Comparators are generally whatever is used as standard of care in the regional setting, but placebos or sham treatments are never used in PCT.  Sometimes additional clinical assessments may be requested to help gauge improvement but they must be consistent with real-world practice. Patient-reported outcomes also may be collected in order to evaluate the impact on daily living and quality of life. 

    While it may sound simple, it isn’t.

    In the absence of blinding patients and observers as to which treatments are being used, it is critical to evaluate if and how assessments of outcomes will be impacted by patients and physicians knowing what treatments they are receiving. It is also essential to determine whether the outcomes of interested will be detectable and recorded in accessible real-world data, like electronic medical records or health insurance claims. Nonetheless, with appropriate evaluation and planning, PCT can be used to address clinical questions of importance to many stakeholders, including patients and health care providers as well as regulators and payers.

    Changing the way we answer questions
    While this is a relatively new research model for the pharma industry, PCT are catching on. Consider ADAPTABLE, a three-year PCT funded by PCORnet, the National Patient-Centered Clinical Research Network, to study whether a daily dose of aspirin will prevent heart attacks and strokes in individuals living with heart disease. The ADAPTABLE study, just starting, will randomize treatments to one of two doses of daily aspirin in 20,000 participants to assess cardiac benefit. Investigators will use existing data sources to track major adverse cardiac events, including hospitalizations and death. The cost of ADAPTABLE is expected to be about $14 million whereas a classical RCT of similar size was recently completed at a cost of roughly $420 million. So, for the same price as a single classical cardiovascular outcomes randomized trial, researchers could conduct 30 different pragmatic trials, pursing many questions of real-world importance.

    There have been several examples of successful PCTs, including the Salford Lung Study (SLS) in Manchester, England which used electronic health record data and National Health Service (NHS) data to recruit and randomize treatments to a population of 2800 consenting patients to examine the safety and effectiveness of a new treatment for chronic obstructive pulmonary disease (COPD). The study ultimately helped the sponsor demonstrate the value of this new treatment for clinicians, patients and payers.

    Regulators are also beginning to show interest in PCTs as a way to establish real world effectiveness and possibly even for label expansions. The US Food and Drug Administration hasn’t issued guidance for using PCTs, however, in May, 2016 the National Institutes of Health (NIH) sponsored a workshop on the Ethical and Regulatory Issues of PCTs; and in January, 2017 the NIH Office of Disease Prevention (ODP) released an online course on how to design and analyze pragmatic and group-randomized trials. The European Medicines Agency (EMA) has also shown a willingness to consider data from PCTs, and references their use in its Scientific guidance on post-authorization efficacy studies.

    While there is no guarantee that regulators will accept PCT data as proof of effectiveness that is sufficient to broaden a label for a product already on the market or to support a health technology assessment, sponsors interested in using this cost-effective approach should meet with regulators and/or payers before starting a PCT to discuss the goals and proposed plan in order to address any concerns those stakeholders may have.  Also PRECIS-2, a checklist to help evaluate all the parameters by which a trial can be pragmatic, should be consulted during the design of a study, since there are many design features that can influence how pragmatic a trial is, and not an absolute dichotomy between classical and pragmatic RCT.

    This study design can have a profound impact on the way we answer real world questions around efficacy, effectiveness and the safety of marketed products going forward — the cost benefits and demonstrated quality that can be achieved with these PCT make them too valuable to ignore.
    Related Searches
    • it
    • study
    • Clinical Trials
    • Testing
    Suggested For You
    PRA Health Sciences Expands Pharmacovigilance Services PRA Health Sciences Expands Pharmacovigilance Services
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19 Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19
    Observational Clinical Research for Real World Evidence Observational Clinical Research for Real World Evidence
    Breaking New Ground: How Industry Collaboration is Transforming Clinical Research Breaking New Ground: How Industry Collaboration is Transforming Clinical Research
    Aptar Pharma’s Electronic Lockout Device Approved by EMA Aptar Pharma’s Electronic Lockout Device Approved by EMA
    In vivo Models Targeting Respiratory Diseases In vivo Models Targeting Respiratory Diseases
    PPD Creates Real-world Research Unit PPD Creates Real-world Research Unit
    AMRI Wins Five-Year NIH Contract AMRI Wins Five-Year NIH Contract
    Real World Evidence Real World Evidence
    How to Maximize Potential and Sidestep Pitfalls of MAPs  How to Maximize Potential and Sidestep Pitfalls of MAPs
    INC Research Makes Executive Appointments INC Research Makes Executive Appointments
    Precision Medicine Precision Medicine
    PPD Awarded NIH Contract for HIV Research  PPD Awarded NIH Contract for HIV Research
    Innate Achieves $15M BMS Milestone Innate Achieves $15M BMS Milestone

    Related Breaking News

    • CRO News
      PRA Health Sciences Expands Pharmacovigilance Services

      PRA Health Sciences Expands Pharmacovigilance Services

      Offers post-marketing services for authorized COVID-19 vaccines and therapeutics, including PASS using Real World Solutions.
      Kristin Brooks 04.22.21

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19

      Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19

      The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions.
      Contract Pharma Staff 12.04.20


    • Clinical Trials | Drug Development

      Observational Clinical Research for Real World Evidence

      ...
      05.19.17

    • Clinical Trials | Drug Development | Information Technology
      Breaking New Ground: How Industry Collaboration is Transforming Clinical Research

      Breaking New Ground: How Industry Collaboration is Transforming Clinical Research

      An increasingly complex clinical trial landscape drives the life sciences industry to support broad collaborations
      Jill Johnston, Vice President, Veeva Vault, Veeva Systems 05.15.17

    Loading, Please Wait..
    Trending
    • Merck KGaA Secures Exclusive Worldwide Rights To Bavencio
    • Codiak BioSciences To File For Chapter 11
    • BioNTech Revenues Slide With Waning Demand For COVID-19 Vaccines
    • How Industry 5.0 Might Benefit Pharmaceutical Manufacturing
    • Jubilant HollisterStier Appoints Chris Preti President
    Breaking News
    • Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories
    • Vantage Nutrition Acquires ComboCap
    • Secarna, SciNeuro Enter Research Agreement for CNS Diseases
    • BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines
    • Codiak BioSciences to File for Chapter 11
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Amorphous Solid Dispersions for Bioavailability Enhancement
    • Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success
    • Manufacturing Dietary Supplements in Economic Uncertainty
    • 2023 Contract Manufacturing Survey
    • New Possibilities for Small Batch Manufacturing
    • Supply Chain Risk Management
    • 3 Ways Pharma Can Outsmart Talent Challenges in 2023
    • Nutraceutical Dosage Trends: Functional Gummies Offer Alternative to Tablets and Capsules
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Melodea Launches New Plastic-Free Packaging Solution
    GOED and NASC Announce Strategic Partnership
    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill
    Coatings World

    Latest Breaking News From Coatings World

    HOFFMANN MINERAL to Focus on Comprehensive Sustainability Strategy
    HMG and Prodrive Renew Technical Partnership
    Eastern Coatings Show Sets Schedule for Technical Papers
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs FemDx Medsystems' FalloView Device
    FDA Clears NeuroRPM Parkinson's Disease Monitoring Tech
    Vaporox Earns FDA Nod for VHT-200 Wound Care Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories
    Vantage Nutrition Acquires ComboCap
    Secarna, SciNeuro Enter Research Agreement for CNS Diseases
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Thread Beauty Expands Cosmetics Line at Target
    The Body Shop Expands its Refill Program in Canada
    Clinique Introduces Digital Retail Concept—Clinique Lab
    Happi

    Latest Breaking News From Happi

    Arbonne Welcomes New Executives
    Total Sales for Naples Soap Company in 2022 Increase 2% Despite Inflation, Supply Chain Issues
    IBA Supports FDA in the MoCRA Rulemaking and Implementation Process
    Ink World

    Latest Breaking News From Ink World

    hubergroup Print Solutions Presents Sustainable Portfolio at PAMEX 2023
    Weekly Recap: Packaging Inks, Toyo Ink Top This Week’s Stories
    Eastern Coatings Show Announces Schedule for Technical Papers
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    eProductivity Software acquires Tharstern Group
    Imageworx details new facility, Avery Dennison tackles recycling and more
    TLMI announces 2022 Eugene Singer Award winners
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Period Care Brand August Launches in Target Stores
    Albany International Announced CEO Succession Plan
    Ahlström Partners to Make Sustainable Butter, Margarine Packaging
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Exactech Boosts AI Expertise with Licensing Deal, Team of Scientists
    Anchor Harvey Celebrates 100th Anniversary in 2023
    Arjun Ishwar Joins Miach Orthopaedics as Sales and Marketing VP
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Honored with Supplier of the Year 2022 Award by Hyundai Motor Group 
    Weekly Recap: Dave Rahami, Zebra, Dracula Technologies Top This Week’s Stories
    Midsummer, UCLA Collaborate on Perovskite-CIGS Tandem Solar Cells

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login